Filing Flows › Ironwood Pharmaceuticals (IRWD) › Q4 2025
Ironwood Pharmaceuticals (IRWD) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Ironwood Pharmaceuticals (IRWD) reported revenue of $47.7M for the fourth quarter 2025 (Q4 2025), -47% from a year earlier and -61% from the quarter before. Operating margin was 14.3%, net loss $2.3M (4.8% of revenue).
Ironwood Pharmaceuticals, Q4 2025: revenue $47.7M (-47% year over year), operating margin 14.3%, net loss $2.3M, operating cash flow $74.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $47.7M | -61% | -47% |
| Operating profit | $6.8M | -91% | — |
| Net earnings | −$2.3M | -106% | — |
| Operating cash flow | $74.6M | +57% | +390% |
What changed
Revenue was $47.7M in Q4 2025, down 47% year over year and down 61% from the previous quarter.
Operating profit was $6.8M, a 14.3% margin (down 20.5 points year over year). Total costs fell 31% while revenue fell 47%. The quarter ended with a net loss of $2.3M, after a profit of $40.1M the previous quarter. Net interest and other expense of $6.3M was the main reason.
Operating cash flow was $74.6M (up 390% year over year). Non-cash charges added back $460K of depreciation and $3.8M of share-based compensation. Working capital and other items added $72.6M. Capital expenditures of −$1K left free cash flow of $74.6M.
Questions
What was Ironwood Pharmaceuticals' revenue in the fourth quarter 2025?
Ironwood Pharmaceuticals (IRWD) reported revenue of $47.7M for the fourth quarter 2025 (Q4 2025), -47% from a year earlier and -61% from the quarter before.
Was Ironwood Pharmaceuticals profitable in the fourth quarter 2025?
Operating profit was $6.8M (14.3% of revenue) and net loss $2.3M.